Long Term Study to Investigate the Efficacy and Safety of an Investigational Medication in Patients with Alopecia Areata

Last Updated:
09/21/2020
Status:
Active/Fully Enrolled
Eligibility:
Age 12+; diagnosed with AA (25% or greater scalp hair loss)
Drug:
PF-06651600
Administration:
Oral
Sponsor: 
Pfizer, Inc.

A clinical research study is currently looking for adolescents and adults with alopecia areata who have lost 25% or more of the hair on their head to participate in a study of an oral investigational medication. The study will explore whether the study drug is safe and can help patients with alopecia areata regrow their hair.

During the course of this study, you will receive the investigational medication for up to 24 months. If you have not previously participated in an ALLEGRO study (B7931005 or B7981015) you will be initially assigned to take 200 mg of the study drug each day for 4 weeks. After these 4 weeks, you will then be assigned to take 50 mg each day for the remaining part of the study.

If you participated and took study drug in the B7931005 or B7981015 ALLEGRO studies in the past, you will be assigned to take 50 mg of the study drug each day.

You may qualify to participate if you:

  • are 12 years of age or older
  • have been diagnosed with alopecia areata
  • have at least 25% scalp hair loss*
*study doctor will assess your amount of hair loss.